Peptides for Lyme disease have no human evidence behind them. No peptide, including thymosin alpha-1, BPC-157, LL-37 or KPV, has been tested against Lyme disease in a published human trial, and when FDA reviewed thymosin alpha-1 it found no clinical studies for Lyme at all.[9] The proven treatment is a 10-day to 4-week course of antibiotics, and most people treated early recover rapidly and completely.[1]
Peptides are still promoted online for “chronic Lyme,” often alongside other unproven therapies. This guide grades each one by its evidence, explains what helps lingering symptoms, and flags the risks. For related compounds, see the longevity and immune peptides hub.
Peptides for Lyme disease: evidence at a glance
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Antibiotics (doxycycline, amoxicillin, cefuroxime) | Human RCTs; standard care | Most early cases recover fully with 10 days to 4 weeks of treatment[1][3] | FDA-approved antibiotics; recommended by CDC and IDSA | — |
| Extended antibiotics for lingering symptoms | Human RCTs | No lasting benefit over placebo in three trials[4][5][6] | Approved drugs, but this use is not recommended[2] | — |
| Thymosin alpha-1 | No evidence, marketing only | FDA found no clinical studies for Lyme[9] | Not approved; advisers voted against compounding in 2024 | Thymosin alpha-1 |
| LL-37 | Animal or lab only | The Lyme bacterium resisted high levels of cathelicidin in lab tests[10] | Not approved; FDA lists safety concerns[12] | LL-37 |
| BPC-157 | No evidence, marketing only | Never studied in Lyme disease | Not approved | BPC-157 |
| KPV | No evidence, marketing only | No human data for any use[11] | Not approved | KPV |
| VIP | No evidence, marketing only | Promoted for mold illness, not studied in Lyme | Not approved for this use | VIP |
“Best supported” here means antibiotics. None of the peptides has evidence that it treats Lyme disease or its after-effects.
What actually treats Lyme disease
CDC says the antibiotics most commonly used are doxycycline, amoxicillin and cefuroxime axetil, and the choice and length depend on symptoms, age, allergies and pregnancy.[1] The 2020 joint guideline from infectious disease, neurology and rheumatology societies covers treatment for each stage, including Lyme arthritis, nerve involvement and Lyme carditis.[3]
Prevention matters too. In some situations a single dose of doxycycline after a tick bite in an area where Lyme is common may lower the risk of infection, so ask your clinician promptly after a bite.[1]
Lingering symptoms: what is known
After a recommended course of antibiotics, some people have months of fatigue, body aches or trouble thinking. CDC calls this post-treatment Lyme disease syndrome (PTLDS) and says its cause is unknown. It discourages the term “chronic Lyme disease” because it implies an ongoing infection that has not been shown.[2]
Researchers have tested whether more antibiotics help. They did not:
- US trials, 2001: 129 patients with well-documented, previously treated Lyme disease received 90 days of IV and oral antibiotics or placebo. The trials stopped early because no difference was emerging; 37% improved on antibiotics versus 40% on placebo among those with antibodies.[4]
- Dutch PLEASE trial, 2016: 280 patients received two weeks of IV ceftriaxone, then 12 weeks of doxycycline, clarithromycin plus hydroxychloroquine, or placebo. Quality-of-life scores did not differ.[5]
- Memory trial, 2008: in 37 patients with memory problems, 10 weeks of IV ceftriaxone improved thinking at week 12, but the gain faded by week 24, and 26% of antibiotic patients had adverse events from the drug or IV line.[6]
CDC notes that most people with prolonged symptoms improve over time without more antibiotics, though it can take months.[2]
The peptides marketed for chronic Lyme
Thymosin alpha-1
Thymosin alpha-1 is a thymus peptide sold abroad as Zadaxin, mainly for hepatitis B. FDA’s 2024 review noted online claims that it treats “long COVID” and chronic Lyme disease, but the agency did not formally evaluate Lyme as a use and noted that it found no clinical studies for it.[9] Our thymosin alpha-1 vs LL-37 comparison covers its trials in other conditions, which have been mostly disappointing.
LL-37
LL-37 is the human member of the cathelicidin family of antimicrobial peptides. That sounds promising for an infection, but a US government lab found the Lyme bacterium was resistant to high concentrations of cathelicidin, which bound poorly to its outer membrane.[10] FDA lists LL-37 among substances with safety concerns, including possible immune reactions and impurities.[12]
BPC-157, KPV and VIP
BPC-157 and KPV are promoted for joint pain, gut symptoms and inflammation. Neither has been studied in Lyme disease. For KPV, FDA found no human data of any kind.[11] Our BPC-157 clinical trials review explains how thin its human evidence is. VIP nasal spray is promoted for mold-related illness; see our VIP and CIRS guide for why that evidence is weak, and note it has not been tested in Lyme.
Why peptides get marketed for Lyme
Lingering symptoms after Lyme disease are real and can be disabling, and there is no approved drug for them.[2] That gap is where peptide marketing lands. The pitch usually rests on one of three ideas: that the immune system needs “boosting,” that hidden infection persists and needs an antimicrobial, or that inflammation needs calming. Each idea borrows a plausible-sounding mechanism from lab work on a different condition.
What is missing is the step that matters: a study in people with Lyme disease or PTLDS showing they feel or function better. Without it, there is no way to know whether a peptide helps, does nothing or makes things worse. The same gap applies to blends that combine several of these peptides.
Why unproven Lyme treatments are risky
A 2015 review found more than 30 alternative treatments marketed for Lyme, from oxygen therapies to stem cells. The authors found no evidence of benefit for any of them, and many were potentially harmful.[8]
The harms are not theoretical. CDC described patients diagnosed with “chronic Lyme disease” who developed septic shock, bone infection, C. difficile colitis and a spinal abscess from their treatments.[7] Unapproved injectable peptides add their own uncertainty: products sold online are not checked for purity or dose, and FDA has warned that some can trigger immune reactions.[12]
What is being studied
Research on lingering Lyme symptoms continues, but none of it involves peptides. One example is a small placebo-controlled trial of intermittent ceftriaxone, recruiting through 2026.[13] Other registered studies test devices, rehabilitation and nerve stimulation.
Questions to ask your clinician
- Was my Lyme disease confirmed with a recommended test, and was I treated with a standard regimen?
- Could my symptoms come from another cause, such as thyroid disease, sleep problems, depression or another infection?[2]
- Which symptom affects my life most, and how can we manage it now?
- If someone offers me a peptide or long-term antibiotics, what is the evidence, and what are the risks?
The bottom line
Lyme disease is a bacterial infection with an effective, guideline-backed treatment: antibiotics. No peptide has been shown to treat it or its after-effects, and the peptides marketed for “chronic Lyme” are untested in people with the condition. For lingering symptoms, the best-supported path is careful evaluation and symptom management with your own clinician. For more on reading claims like these, see our guide to animal versus human peptide studies.
This is general information, not medical advice.
